BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The first approach made use of the CML mouse model’s ability to induce and eventually suppress BCR::ABL expression upon tetracycline discontinuation (Tet-off) and subsequent re-administration (Tet-on); hence we referred to this treatment as Tet-off-Tet-on (TOTO).